Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway
AssigneeAc Bioscience
InventorChristian Auclair
Life of this patent
Estimating the term…
Abstract
The use of a neoadjuvant prior to chemotherapy. A sphingosine-1-phosphate pathway activator for use in the treatment of cancer as a neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate lyase inhibitors. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent or a sequential radiotherapy.
Claims8
A method of treatment of pancreatic cancer presenting a sprouting angiogenesis of blood vessels in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1-(4-(1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime to increase sphingosine-1-phosphate plasmatic concentration to a level in said subject to suppress the sprouting angiogenesis and stabilize the blood vessels;
- then administering a sequential chemotherapy involving gemcitabine;
- wherein 1-(4-(1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime enhances efficacy of the sequential chemotherapy involving gemcitabine.
Dependencies are inferred from the claim text.